Please login to the form below

Not currently logged in
Email:
Password:

blood cancer

This page shows the latest blood cancer news and features for those working in and with pharma, biotech and healthcare.

Ex-Pharmacyclics CEO invests $25m in Summit

Ex-Pharmacyclics CEO invests $25m in Summit

The heady valuation of the Pharmacyclics deal was largely on the back of Imbruvica (ibrutinib), a blood cancer therapy that  made more than $2.5bn in sales for AbbVie in the

Latest news

  • Dragonfly signs Celgene as partner for NK cell platform Dragonfly signs Celgene as partner for NK cell platform

    Celgene – one of the top blood cancer companies – has seen enough to encourage it to license two of the eight programmes at $12m apiece plus development milestones and royalties, before the ... for blood cancers that it expects to approach $10bn in

  • Dutch biotech Argenx claims $1.8bn licensing deal with J&J Dutch biotech Argenx claims $1.8bn licensing deal with J&J

    Deal centres around blood cancer candidate cusatuzumab. Argenx of the Netherlands has licensed a drug for blood cancers to Johnson &Johnson in a deal that gives it a hefty $300m upfront ... AML continues to be an aggressive and deadly cancer of the blood

  • Grail to initiate largest ever UK cancer screening study Grail to initiate largest ever UK cancer screening study

    Will start testing on 50, 000 people in early 2019. Genomics company Grail has revealed ambitious plans to deploy its investigational cancer detecting blood test into 50, 000 people in what ... Both subgroups will receive the blood test, which uses

  • Astellas, Catalyst approvals set up record year for FDA approvals Astellas, Catalyst approvals set up record year for FDA approvals

    Xospata has been cleared as a single-agent treatment for FLT3-positive AML, which the FDA notes is a particularly aggressive form of the blood cancer with a high risk of ... Roughly half of LEMS cases are secondary to cancers, and particularly small cell

  • Pfizer gets first FDA nod for hedgehog inhibitor in AML Pfizer gets first FDA nod for hedgehog inhibitor in AML

    smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... Erivedge has been discontinued for AML and other blood cancers, but remains in mid-stage development for solid tumours including beast, gastric, pancreatic and lung cancer,

More from news
Approximately 9 fully matching, plus 212 partially matching documents found.

Latest Intelligence

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others. ... Breast cancer drug Ibrance will be one of the biggest growth drivers for the company, as it looks

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... The CAR-Ts have transformed the treatment of childhood ALL – an otherwise incurable blood cancer – and have been shown to work in

  • Deal Watch December 2015 Deal Watch December 2015

    Also during the month AstraZeneca announced the acquisition of 55% for $4bn of Acerta which has a BTK inhibitor in phase III for blood cancer. ... Acerta has phase III BTK inhibitor for blood cancer. 4, 000.

  • Taking a strategic approach Taking a strategic approach

    proposed submitting further evidence and an amended patient access scheme for its prostate cancer drug. ... In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    485. AstraZeneca/Celgene. Exclusive collaboration. MEDI4736 - an investigational checkpoint inhibitor in serious blood cancers. ... 85. Agios Pharmaceuticals / Celgene. R&D collaboration and profit share. AG-881 IDH (isocitrate dehydrogenase) mutant

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics